International experience in controlling pharmaceutical expenditure: Influencing patients and providers and regulating industry – a systematic review

Journal of Health Services Research and Policy

Volumn 20, Issue 1, 2015, Pages 52-59

  Lee, Iyn Hyang ^a   Bloor, Karen ^b   Hewitt, Catherine ^b   Maynard, Alan ^b  

^a Yeungnam University   (South Korea)

^b UNIVERSITY OF YORK   (United Kingdom)

Author keywords

Pharmaceutical industry; Pharmaceutical policy; Prescribing; Systematic review; User charges

Indexed keywords

ESSENTIAL DRUG; NONSTEROID ANTIINFLAMMATORY AGENT;

ACT; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; FOLLOW UP; HEALTH CARE POLICY; HEALTH PERSONNEL ATTITUDE; HUMAN; LICENSING; PATIENT ATTITUDE; PHARMACEUTICAL CARE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PROFIT; REIMBURSEMENT; SYSTEMATIC REVIEW; VULNERABLE POPULATION; COMMERCIAL PHENOMENA; COST; DRUG UTILIZATION; ECONOMICS; FEE; HEALTH CARE QUALITY; MEDICAL EDUCATION; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME;

COMMERCE; COST CONTROL; COST SHARING; DRUG COSTS; DRUG UTILIZATION; EDUCATION, MEDICAL, CONTINUING; FEES, PHARMACEUTICAL; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; QUALITY OF HEALTH CARE; TREATMENT OUTCOME;

EID: 84927716407     PISSN: 13558196     EISSN: 17581060     Source Type: Journal    
DOI: 10.1177/1355819614545675     Document Type: Article

References (40)

1. Mossialos E, Walley T and Mrazek M. Regulating pharmaceuticals in Europe: an overview. In: Mossialos E, Mrazek M and Walley T (eds) Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality. Maidenhead: Open University Press, 2004.
2. Higgins JPT and Green S. Cochrane effective practice and organisation of case group. Suggested risk of bias criteria for EPOC reviews, http://www.epoc.cochrane.org/epocauthor-resources (2008, accessed 23 July 2014).
3. Health and Social Care Information Centre. Prescriptions dispensed in the community 2002–2012. Leeds: HSCIC, 2013.
4. Gibson TB, Mark TL, McGuigan KA, et al. The effects of prescription drug copayments on statin adherence. Am J Manag Care 2006; 12: 509–517.
5. Lexchin J and Grootendorst P. Effects of prescription drug user fees on drug and health services use and on health status in vulnerable populations: a systematic review of the evidence. Int J Health Serv 2004; 34: 101–122.
6. Soumerai SB, Ross-Degnan D, Avorn J, et al. Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. New Engl J Med 1991; 325: 1072–1077.
7. Starmans B, Janssen R, Schepers M and Verkocijen M. The effect of a patient charge and a prescription regulation on the use of antihypertensive drugs in Limburg, The Netherlands. Health Policy 1994; 26(3): 191–206.
8. Valles JA, Barreiro M, Cereza G, et al. A prospective multicenter study of the effect of patient education on acceptability of generic prescribing in general practice. Health Policy 2003; 65: 269–275.
9. Gurwitz JH, McLaughlin TJ and Fish LS. The effect of an Rx-to-OTC switch on medication prescribing patterns and utilization of physician services: the case of vaginal antifungal products. Health Service Res 1995; 30: 672–685.
10. Charlton ME, Levy BT, High RR, et al. Effects of health savings account-eligible plans on utilization and expenditures. Am J Manage Care 2011; 17: 79–86.
11. Mason J, Freemantle N, Nazareth I, et al. When is it costeffective to change the behavior of health professionals? JAMA 2001; 286: 2988–2992.
12. Wei CK, Wang SM and Yeh MK. Doctor pharmaceutical utilization behaviour changed by the global budget programme strategies on hypertensive outpatient prescription. J Eval Clin Practice 2012; 18: 262–268.
13. MacBride-Stewart SP, Elton R and Walley T. Do quality incentives change prescribing patterns in primary care? An observational study in Scotland. Family Practice 2008; 25: 27–32.
14. Bradlow J and Coulter A. Effect of fundholding and indicative prescribing schemes on general practitioners’ prescribing costs. BMJ 1993; 307: 1186–1189.
15. O’Malley AJ, Frank RG, Kaddis A, et al. Impact of alternative interventions on changes in generic dispensing rates. Health Service Res 2006; 41: 1876–1894.
16. Martens JD, Werkhoven MJ, Severens JL, et al. Effects of a behaviour independent financial incentive on prescribing behaviour of general practitioners. J Eval Clin Practice 2007; 13: 369–373.
17. Chu H-L, Liu S-Z and Romeis JC. The effects of physicians’ financial incentives on the effectiveness of Taiwan’s outpatient drug copayment policy. Drug Inform J 2008; 42: 493–502.
18. Chu H-L, Liu S-Z and Romeis JC. Do drug price adjustment policies work? The impact of physician financial incentive plans on the implementation of drug cost containment mechanisms. Drug Inform J 2010; 44: 189–198.
19. Andersson K, Bergstrom G, Petzold MG, et al. Impact of a generic substitution reform on patients’ and society’s expenditure for pharmaceuticals. Health Policy 2007; 81: 376–384.
20. Bond C, Matheson C, Williams S, et al. Repeat prescribing: a role for community pharmacists in controlling and monitoring repeat prescriptions. Br J Gen Practice 2000; 50: 271–275.
21. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Paris: Organisation for Economic Co-operation and Development, 2000.
22. Aaserud M, Dahlgren AT, Kosters JP, et al. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database of Systematic Reviews 2006; CD005979.
23. Grootendorst PV, Marshall JK, Holbrook AM, et al. The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs. Health Service Res 2005; 40: 1297–1317.
24. Usher C, Tilson L, Bennett K, et al. Cost containment interventions introduced on the community drugs schemes in Ireland-evaluation of expenditure trends using a national prescription claims database. Clin Therapeut 2012; 34: 632–639.
25. Hutton J, Borowitz M, Oleksy I, et al. The pharmaceutical industry and health reform: lessons from Europe. Health Aff 1994; 13: 98–111.
26. House of Commons Health Committee. National Institute for Health and Clinical Excellence (NICE) 8th report of session 20122013. HC782. London: The Stationery Office, 2013.
27. Lundkvist J, Jonsson B and Rehnberg C. The costs and benefits of regulations for reimbursement of new drugs. Health Policy 2006; 79: 337–344.
28. Carpenter D, Zucker EJ and Avorn J. Drug-review deadlines and safety problems. New Engl J Med 2008; 358: 1354–1361.
29. Department of Health. Pharmaceutical price regulation 2009. London: Department of Health, 2008.
30. Borrell JR. Pharmaceutical price regulation. A study on the impact of the rate-of-return regulation in the UK. Pharmacoeconomics 1999; 15: 291–303.
31. Freemantle N and Bloor K. Lessons from international experience in controlling pharmaceutical expenditure. I: Influencing patients. BMJ 1996; 312: 1469–1471.
32. Barer M, Evans R and Stoddart G. Controlling health care costs by direct charges to patients, snare or delusion? Toronto: Ontario Economic Council-Occasional Paper 10, 1979.
33. Ryan M and Birch S. Charging for health care: evidence on the utilisation of NHS prescribed drugs. Social Sci Med 1991; 33: 681–687.
34. Bloor K and Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure II: Influencing doctors. BMJ 1996; 312: 1525–1527.
35. Doran T, Fullwood C, Gravelle H, et al. Pay-forperformance programs in family practices in the United Kingdom. N Engl J Med 2006; 355: 375–384.
36. Fleetcroft R and Cookson R. Do the incentive payments in the new NHS contract for primary care reflect likely population health gains? J Health Serv Res Policy 2006; 11: 27–31.
37. Doran T, Kontopantelis E, Valderas JM, et al. Effect of financial incentives on incentivised and non-incentivised clinical activities: longitudinal analysis of data from the UK quality and outcomes framework. BMJ 2011; 28: d3590.
38. Gravelle H, Sutton M and Ma A. Doctor behaviour under a pay-for-performance contract: evidence from the quality and outcomes framework. University of York: Centre for Health Economics Research Paper 28, 2007.
39. Cashin C. United Kingdom: Quality and Outcomes Framework (QOF). Washington: The World Bank, 2011.
40. Bloor K, Maynard A and Freemantle N. Lessons from international experience in controlling pharmaceutical expenditure III Regulating industry. BMJ 1996; 313: 33–35.